Barclays lowered the firm’s price target on Bristol-Myers to $65 from $66 and keeps an Equal Weight rating on the shares. The analyst says the company’s Q1 update reinforces rather than addresses key questions.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY: